

InvestPro

Top Idea Picks

April 2025

Investment Ideas:

High Conviction Stocks Idea Attributes

- **Company:** a) Sound / resilient business; b) Consistent strong financials; c) High growth potential; and d) High return on invested capital
- **Industry:** a) Market leaders / Strong brand value; b) High growth opportunities; c) Strong entry barriers
- **Management:** a) Visionary Leadership; b) Strong & Effective Management; and c) High corporate access, including promoters and CXOs
- **DevenChoksey Differentiators:** a) Analytics that predicts market movements; and b) High quality actionable research

Axis Bank Ltd

Strengthening the core with a resilient franchise and structural growth levers

BUY | Target Price: 1,283 | Upside: 18.1%

[Read Report](#)

Glenmark Pharmaceuticals Ltd

Strong India and Europe momentum lays foundation for sustainable, margin-accretive growth

BUY | Target Price: 1,768 | Upside: 17.2%

[Read Report](#)

Infosys Ltd

Infosys secures broad-based wins across verticals; TCV at USD 2.5 Bn

BUY | Target Price: 2,154 | Upside: 41.1%

[Read Report](#)

Lupin Ltd

Portfolio strength, pipeline visibility, and geographic expansion support robust outlook

BUY | Target Price: 2,472 | Upside: 26.5%

[Read Report](#)

State Bank of India Ltd

Market leader poised for sustained growth and profitability

BUY | Target Price: 915 | Upside: 18.5%

[Read Report](#)

Uno Minda Ltd

Driving growth through strategic expansion

BUY | Target Price: 1,208 | Upside: 35.7%

[Read Report](#)

Note: Prices as on 01st April 2025; Source: FactSet, DevenChoksey Research

Strengthening the core with a resilient franchise and structural growth levers

CMP	Target	Potential Upside	Category	Market Cap (INR Mn)	Recommendation	Sector
INR 1,086	INR 1,283	18.1%	Large Cap.	INR 33,60,995	BUY	Banking

AXSB is a prominent Indian bank that provides a wide range of financial services to a diverse clientele in both the corporate and retail sectors. The Bank holds a robust position in the market and is supported by a seasoned management team.

Structural NIM drivers steadily improving: AXSB continues to make structural improvements that support Net Interest Margin (NIM) resilience, with progress visible across multiple vectors. The balance sheet mix has improved, with loans and investments forming 90.0% of total assets as of December 31, 2024, an 89 bps YoY increase. The share of retail and CBG advances rose to 71% of total advances, up 167 bps YoY, driving better portfolio yields. Additionally, low-yielding RIDF bonds have declined by INR 83,910 Mn YoY, reducing their share in total assets to 1.10% from 1.80% a year ago. On the liabilities side, AXSB continues to maintain industry-best outflow ratios at 25.3%, reflecting high-quality liabilities. While there was a decline in QAB CASA to 39.0%, the impact was offset by a favorable rate benefit across parts of the liability stack. These structural levers continue to reinforce the bank's NIM trajectory amidst a challenging rate environment.

Building a resilient franchise with quality growth and cost discipline: AXSB has made significant progress in building a resilient, all-weather franchise. The bank remains focused on three key areas—deposit quality and growth, retail asset quality, and costs—with a clear path toward sustainable outcomes. On deposits, AXSB has delivered well on quality and cost, with improved granularization, a 320-bps improvement in outflow ratio, and only a 3 bps rise in cost of funds over the last three quarters. While period-end growth was impacted by macro factors, quarterly average deposit growth at 13.0% remains above industry. Project Triumph is strengthening the deposit franchise through new branch additions, strong SA NTB deposit growth (15.0% YoY), and healthy traction in salary credits and premium segments, including a 24.0% YoY rise in NTB salary uploads and 26% YoY growth in Burgundy AUMs. Retail asset quality is undergoing a normalization cycle, with conservative recognition and provisioning policies in place. Cost discipline is evident, with expense growth moderated to 1.0% YoY. These developments position AXSB well as it navigates the current cycle.

Prudent approach to retail asset quality amid industry-wide stress: AXSB continues to maintain one of the best asset quality metrics among large peer banks, backed by strong net NPA and provision coverage levels. While bureau data indicates rising delinquencies in unsecured segments across the industry—driven by credit hungriness and over-leverage, AXSB's exposure to high-risk portfolios like MFI remains minimal at ~1% of retail loans. The bank has adopted a cautious stance, especially in light of recent regulatory actions, and has proactively recalibrated policies in personal loans and cards where early risk signals emerged. Regular portfolio monitoring, early warning triggers, and risk-based pricing have helped keep delinquencies within acceptable thresholds. Furthermore, investments in tech-enabled collections infrastructure are enhancing recovery efficiency, reinforcing AXSB's prudent approach toward unsecured lending amid a challenging environment.

We maintain our target price downwards to INR 1,283 per share (unchanged) by assigning a 1.7x P/ABV multiple to the FY27E adjusted book value of INR 754.7 per share. This implies a left-over upside of 18.1% over the CMP. We have a "BUY" rating on the shares of Axis Bank Ltd since 20th February 2025.

Key Financials

Particulars (INR Mn)	FY24	FY25E	FY26E	FY27E
NII	498,945	542,437	576,163	649,615
PPOP	371,232	426,129	463,301	526,870
PAT	248,615	261,378	280,346	319,887
EPS (INR / Share)	80.7	84.4	90.6	103.4
Adj. BVPS (INR / Share)	478.9	561.6	651.4	754.7
NIM	3.9%	3.8%	3.7%	3.7%
Advances Growth YoY	14.2%	8.0%	12.1%	11.9%


Source: DevenChoksey Research

Shareholding Pattern (%)

Particulars	Dec-24	Sep-24	Jun-24
Promoters	8.2	8.3	8.3
FIIIs	47.3	51.8	53.4
DIIIs	37.5	33.2	31.6
Others	7.0	6.7	6.7
Total	100.0	100.0	100.0

Source: BSE

Share Price Chart



Source: BSE

Strong India and Europe momentum lays foundation for sustainable, margin-accretive growth

CMP	Target	Potential Upside	Category	Market Cap (INR Mn)	Recommendation	Sector
INR 1,509	INR 1,768	17.2%	Mid Cap.	425,878	BUY	Pharmaceuticals

Glenmark Pharma operates 10 manufacturing facilities and 4 R&D centers, with branded markets accounting for 60.0% of its total revenue. The company has a presence in over 80 countries and maintains a global therapeutic focus on dermatology, respiratory, and oncology. In India, its portfolio also includes cardiovascular and diabetes therapies.

Strong revenue growth led by robust India and Europe performance

For Q3FY25, the revenue increased 35.1% YoY, driven by strong growth in India and Europe. Revenue from the India segment (32.0% of the revenue) grew 300.2% YoY, was fueled by new launches, outperformed IPM (Indian Pharmaceutical Market) in key therapeutic areas, strong consumer brands, and a low base in Q3FY24. Revenue from the Europe segment (22.0% of the revenue) grew 14.8% YoY, was driven by strong respiratory portfolio performance, market share gains in key regions, regulatory approvals, and a strategic focus on branded products. Management remains confident in achieving the guided revenue growth for FY25E (INR 135,000 Mn), despite currency fluctuations and short-term challenges. India Business is expected to maintain 9.0-10.0% growth YoY, driven by new launches in diabetes (GLP-1 agonists), dermatology, and oncology.

Company eyes structural margin gains from FY26E driven by high-value segments

EBITDA was at INR 6,002 Mn against an operating loss of INR 2,086 Mn in Q3FY24 and was flat QoQ. EBITDA margin was at 17.7% (+19 bps QoQ), which was supported by a better product mix, cost efficiencies, and brand-driven expansion. Adj. Net profit stood at INR 3,480 Mn against an Adj. net loss of INR 3,934 in Q3FY24 and an Adj. net profit of INR 3,542 Mn in Q2FY25. The company expects a 100 bps to 150 bps YoY improvement in EBITDA margin from FY26E onwards, driven by higher-margin branded sales in India and Europe and new respiratory and injectable launches in the US.

Branded portfolio to drive future growth across key therapy areas

LIRAFIT (Biosimilar of Liraglutide) is the first GLP-1 (Glucagon-Like Peptide-1) biosimilar launched in India, targeting diabetes. The product has seen good traction post-launch. JABRYUS (Abrocitinib – Partnered with Pfizer) is a novel oral treatment for moderate-to-severe atopic dermatitis, well received by dermatologists. RYALTRIS continued to gain market share across multiple European countries where it has been launched. Other key respiratory brands like Salmex and Asthmex maintained strong market positions. The branded business in European operations sustained its growth trajectory, particularly in Western Europe. MHRA approval for WINLEVI in the UK strengthened Glenmark's dermatology portfolio in Europe.

We expect the revenue to grow at 11.5% CAGR and EBITDA to grow at 37.2% CAGR over FY24-FY27E. Currently, the stock is trading at a PE multiple of 24.7x/22.2x based on FY26E/FY27E EPS, respectively. We assign a PE multiple of 26.0x to arrive at a target price of INR 1,768, which will have an upside potential of 17.2%. We have a BUY rating on the stock since 18th February 2025.

Key Financials

Particulars (INR Mn)	FY24	FY25E	FY26E	FY27E
Revenue	118,131	134,689	148,886	163,655
EBITDA	11,953	23,763	27,838	30,845
Adj PAT	(9,980)	13,733	17,238	19,193
Adj. EPS (INR)	(35.4)	48.7	61.1	68.0
EBITDA Margin	10.1%	17.6%	18.7%	18.8%
Adj. NPM	-8.4%	10.2%	11.6%	11.7%


Source: DevenChoksey Research

Shareholding Pattern (%)

Particulars	Dec-24	Sep-24	Jun-24
Promoters	46.7	46.7	46.7
FIIIs	23.5	23.1	21.0
DIIIs	13.9	13.2	13.9
Others	15.9	17.1	18.4
Total	100	100	100

Source: BSE

Share price performance



Source: BSE

Infosys secures broad-based wins across verticals; TCV at USD 2.5 Bn

CMP	Target	Potential Upside	Category	Market Cap (INR Mn)	Recommendation	Sector
INR 1,527	INR 2,154	41.1%	Large Cap.	63,55,324	BUY	IT

Infosys Limited is a leading global IT services and consulting company headquartered in Bengaluru, India. Founded in 1981, the company provides various services, including digital transformation, cloud computing, artificial intelligence, application development, and business process management. With a client base spanning over 50 countries, Infosys is known for its strong delivery capabilities, innovation-driven approach, and deep domain expertise across industries like financial services, retail, healthcare, and manufacturing.

Robust growth across verticals and regions (excl. Retail and RoW)

Infosys's revenue for Q3FY25 stood at INR 4,17,640 Mn, reflecting a 7.6% YoY increase (+1.9% QoQ). EBIT of INR 89,120 Mn grew by 11.9% YoY (+3.0% QoQ); EBIT margins stood at 21.3% (+83bps YoY/ 24bps QoQ). PAT jumped by 11.6% YoY (+4.7% QoQ) to INR 68,220 Mn; PAT margins improved by 59bps YoY (+44bps QoQ) to 16.3%.

The manufacturing sector (15.5% of revenue) expanded by 10.7% YoY CC, while Energy, Utilities, Resources, & Services (EURS – 13.5% of revenue) increased by 8.6% YoY CC. Hi-Tech (7.9% of revenue) grew by 8.4% YoY CC, and the BFSI segment (27.8% of revenue) saw a 6.1% YoY CC growth. Retail remained flat YoY (+0.1% YoY CC). The BFSI sector in the U.S. continues to experience an increase in discretionary spending across capital markets, mortgages, cards, and payments, driving a third consecutive quarter of volume growth. This growth is coupled with a revival in European financial services in Q3FY25.

The European automotive sector remains weak, while growth continues in areas like engineering, IoT, supply chain, cloud ERP, and digital transformation. Vendor consolidation is expanding existing relationships, particularly in the communications sector, which faces macroeconomic pressures and rising costs. Discretionary spending stays muted, with growth driven by large deal wins focused on efficiency and consolidation. Infosys reported robust growth in Europe (29.8% of revenue), delivering 12.2% YoY CC, while North America (58.4% of revenue) posted a modest growth of 4.8% CC YoY. RoW (8.7% of revenue) declined 11.1% YoY CC, and India (3.1% of revenue) grew by 40.1% YoY CC.

Infosys secures 17 large deals, expanding across key verticals and regions

Infosys closed Q3FY25 with a Total Contract Value (TCV) of USD 2.5 Bn, down 21.9% YoY (+4.2% QoQ), with 63.0% of the wins being net new business. The company secured 17 large deals, including 5 in BFSI, 4 in communications, 3 in manufacturing, 2 each in retail and E&U, and 1 in hi-tech. Geographically, 11 deals were signed in North America and 6 in Europe, including a BOT deal for a GCC setup in India. For 9MFY25, large deal wins totaled 72, with a TCV of approximately USD 9.0 Bn, of which 55.0% was net-new.

We expect Revenue/ EBIT/ PAT to grow at a CAGR of 8.9%/10.3%/8.1% over FY24-FY27E. We assign a P/E of 27.0x on FY27E EPS of INR 79.7 to arrive at a target price of INR 2,154 per share. This implies a leftover upside of 41.1% from current levels. Accordingly, we have a BUY rating on the shares of Infosys since 18th Jan 2025.

Key Financials

Particulars (INR Mn)	FY24	FY25E	FY26E	FY27E
Revenue	15,36,710	16,44,256	17,96,766	19,82,953
EBIT	3,17,470	3,44,691	3,85,598	4,26,346
EBITDA Margin	20.7%	21.0%	21.5%	21.5%
Adj Net Profit	2,62,320	2,64,307	3,02,364	3,31,186
Adj PAT Margin	17.1%	16.1%	16.8%	16.7%
Adj EPS	63.4	63.7	72.8	79.7


Source: DevenChoksey Research

Shareholding Pattern (%)

Particulars	Dec-24	Sept-24	Jun-24
Promoters	14.4	14.4	14.6
FIIIs	33.3	33.3	32.7
DIIIs	38.2	37.8	37.3
Others	14.1	14.5	15.4
Total	100	100	100

Source: BSE

Share Price Chart



Source: BSE

Portfolio strength, pipeline visibility, and geographic expansion support robust outlook

CMP	Target	Potential Upside	Category	Market Cap (INR Mn)	Recommendation	Sector
INR 1,955	INR 2,472	26.5%	Large Cap.	892,767	BUY	Pharmaceuticals

Lupin has a strong presence in over 100 countries, with key markets including the United States, India, and EMEA. Lupin's product portfolio spans key therapeutic areas such as cardiovascular, diabetology, respiratory, dermatology, central nervous system (CNS), and anti-infectives. Lupin operates 15 manufacturing sites and 7 R&D centers globally.

Key geographies deliver strong growth driven by complex generics and chronic therapies

For Q3FY25, the revenue increased 11.0% YoY, supported by strong growth across key geographies such as North America, India, and EMEA. Revenue from North America (37.8% of revenue) grew 12.3% YoY, driven by growth in new product launches, expansion in complex generics and respiratory portfolio. Revenue from India (34.4% of revenue) grew 11.9% YoY, led by growth across key therapy mix, an increase in product launches, and an increase in chronic therapy contribution. Revenue from EMEA (11.1% of revenue, Europe and South Africa) grew 20.9% YoY, driven by strong double-digit expansion in Germany and the UK, and increased sales from key respiratory products.

Improved mix and efficiencies support margin uplift; FY25E guidance intact

Gross margin expanded 336 bps YoY to 70.2%, supported by a better product mix including complex generics and speciality products, and a favourable cost environment. EBITDA increased 33.7% YoY, EBITDA margin expanded 402 bps YoY to 23.7%, primarily due to increase in gross margins, and operating leverage. The company believes they should be able to deliver EBITDA margins between 23.0% and 23.5% in FY25E.

R&D focus and recent acquisitions strengthen pipeline and diabetes portfolio

Lupin's complex generics portfolio accounts for ~35.0% of North American sales. The company plans to file 30+ ANDAs in the next two years, with over 50.0% being complex products. Products like Albuterol (23.0% market share), Tiotropium (29.6% share), and Arformoterol (30.3% share) continue to drive sales. Low single-digit price declines in base products partially offset the volume growth from existing products and contributions from new product launches in the U.S. market. The company anticipates its US business to deliver double-digit growth in FY25E, ahead of its earlier guidance of high single-digit growth in the segment. The company acquired the Huminsulin range of products from Eli Lilly and three trademarks from Boehringer Ingelheim for the Indian market, strengthening its diabetes portfolio. A significant portion of the R&D spend is attributed to the company's complex generics portfolio, specifically five nasal sprays expected to be filed in Q4FY25E.

We expect the revenue to grow at 13.1% CAGR and PAT to grow at 35.9% CAGR over FY24-FY27E. Currently, the stock is trading at a PE multiple of 24.5x/18.7x based on FY26E/FY27E EPS, respectively. We assign a PE multiple of 23.6x to arrive at a target price of INR 2,472, which will have an upside potential of 26.5%. We have a BUY rating on the stock since 13th February 2025.

Key Financials

Particulars (INR Mn)	FY24	FY25E	FY26E	FY27E
Revenue	198,056	225,819	252,640	286,180
EBITDA	35,947	52,323	59,249	70,734
Adj PAT	18,999	33,214	36,403	47,695
Adj. EPS (INR)	41.7	72.9	79.9	104.7
EBITDA Margin	18.2%	23.2%	23.5%	24.7%
Adj. NPM	9.6%	14.7%	14.4%	16.7%


Source: DevenChoksey Research

Shareholding Pattern (%)

Particulars	Dec-24	Sept-24	Jun-24
Promoters	47.0	47.0	47.0
FIIIs	22.0	21.5	19.3
DIIIs	24.7	25.1	26.8
Others	6.3	6.4	6.9
Total	100	100	100

Source: BSE

Share price performance



Source: BSE

Market leader poised for sustained growth and profitability

CMP	Target	Potential Upside	Category	Market Cap (INR Mn)	Recommendation	Sector
INR 772	INR 915	18.5%	Large Cap.	INR 68,83,113	BUY	Banking

State Bank of India Ltd (SBIN) offers a wide range of products and services through its various branches and outlets, joint ventures, subsidiaries, and associate companies. Since it is the market leader in the Indian banking industry, the Bank's performance is an indicator of Indian economy.

Dominant market franchise with strong FY25E growth visibility: SBIN leverages its extensive geographic reach and diversified product portfolio. This strategic positioning enables the bank to maintain a dominant market share across multiple business segments. As of December 31, 2024, the bank's credit book stood at INR 40,046 Bn, a growth of 13.8% YoY (+3.8% QoQ), led by 14.1% YoY growth in domestic advances. Domestic growth was driven by healthy growth in the SME (18.7% YoY) and Agri (15.3% YoY) segments. SBIN maintained its credit growth guidance of 14.0%-16.0% for FY25E, with above 14.0% YoY growth in domestic loans. The Foreign credit growth is expected to double-digit (~10.0-12.0% YoY) with trade finance adjustments. SBIN is monitoring trade policy shifts, particularly in the U.S. & China, to adjust strategy. Corporate advances of 14.9% YoY growth were driven by CapEx demand. Corporate credit pipeline as of December 31, 2024, stood at INR 4.83 Tn, of which INR 2.22 Tn was sanctioned, and INR 2.61 Tn was under process. The major loan sectors include infrastructure, energy, and large industrial projects. Thus, in FY25E, SBIN expects corporate growth to be in the range of 12.0%-14.0% YoY.

Robust asset quality backed by sufficient provisioning buffer against any macro-uncertainties: The gross NPA ratio was 2.07%, an improvement of 35 bps YoY (+6 bps QoQ), while the net NPA ratio improved by 11 bps YoY (stable QoQ) at 0.53% as of December 31, 2024. The SME GNPA ratio improved to 3.47% (+16 bps QoQ), while Corporate GNPA improved further to 2.03% from 2.08% as of September 30, 2024. The agri NPAs reported an improvement of 38 bps QoQ to 9.06%. As of December 31, 2024, the Provision Coverage Ratio (PCR) stood at 74.7%, an improvement of 49 bps YoY, while the PCR, including AUCA, stood at 91.7% (an improvement of 25 bps YoY). On the restructuring side, its total exposure under COVID-19 Resolution Plans 1 and 2 stood at INR 137.1 Bn as of December 31, 2024. The bank has allocated an additional INR 41,720 Mn for restructured standard accounts. The bank will maintain its credit cost ratio below 1.0% in FY25E.

Sustained profitability driving superior return ratios: SBIN delivered strong profitability in Q3FY25 with ROA of 1.04% (+42 bps YoY) and ROE of 21.5%. The bank is well on track to maintain ROA above 1.0% and ROE above 20.0% through FY25E and beyond. ROA has steadily improved since FY19, led by margin expansion, cost efficiencies, and better credit underwriting. As of December 31, 2024, the capital adequacy ratio (including 9MFY25 profits) stood at 14.50%, with CET-1 at 10.99%, indicating sufficient headroom for growth. The bank remains open to raising additional capital, if required, to support future balance sheet expansion.

Given the favorable risk-reward dynamics, we maintain our target price of INR 915 (unchanged), valuing the standalone bank at 1.15x FY27E ABV (adj. book value of INR 599.3/ share) and subsidiaries at INR 226 per share. This implies the left-over upside of 18.5% from the CMP. We have Buy rating on the shares of State Bank of India Ltd since 10th February 2025.

Key Financials

Particulars (INR Mn)	FY24	FY25E	FY26E	FY27E
NII	1,598,758	1,672,272	1,855,733	2,071,177
PPOP	937,972	1,062,173	1,196,488	1,334,420
PAT	610,766	704,273	765,191	844,744
Adj. BVPS	399.1	461.4	527.0	599.3
NIM	3.0%	2.8%	2.8%	2.8%
Advances Growth	15.8%	13.0%	13.0%	12.0%


Source: DevenChoksey Research

Shareholding Pattern (%)

Particulars	Dec-24	Sep-24	Jun-24
Promoters	57.4	57.5	57.5
FIIIs	10.3	10.7	11.2
DIIIs	24.9	24.1	23.6
Others	7.4	7.7	7.7
Total	100.0	100	100

Source: BSE

Share Price Chart



Source: BSE

Driving growth through strategic expansion

CMP	Target	Potential Upside	Category	Market Cap (INR Mn)	Recommendation	Sector
INR 890	INR 1,208	35.7%	Mid Cap.	5,11,776	BUY	Auto ancillary

Uno Minda Limited, established in 1958, is a leading global manufacturer of automotive solutions and systems, supplying Tier-1 components to OEMs. The company specializes in automotive switching, lighting, acoustics, seating systems, and alloy wheels. With over 73 manufacturing plants worldwide and a strong focus on electric vehicle technologies, Uno Minda is committed to innovation and sustainability in the automotive industry.

Broad-based revenue growth, except for the Acoustics and Seating segment

In Q3FY25, Switching revenue (25.0% of revenue) stood at INR 10,450 Mn, growing 12.6% YoY but declining 1.1% QoQ, supported by higher kit value and a strong recovery in the two-wheeler segment. Lighting revenue (23.5% of revenue) came in at INR 9,820 Mn, up 15.3% YoY and 1.2% QoQ, aided by robust demand across 2W and 4W OEMs, new launches, and capacity expansion through the Khed lighting plant. Casting revenue (18.4% of revenue) grew 12.0% YoY to INR 7,680 Mn, though down 8.8% QoQ, led by increased capacity, particularly in 2W alloy wheels. Seating revenue (6.5% of revenue) stood at INR 2,730 Mn, down 0.4% YoY and 4.5% QoQ, due to weak European exports despite domestic growth in pneumatic seat supplies. The Acoustic segment (4.4% of revenue) reported INR 1,840 Mn in revenue, declining 8.9% YoY and 1.1% QoQ, impacted by softness in the European auto market affecting Clarton Horn operations. The company remains positive on long-term growth, supported by strong domestic demand, rising EV adoption, new product launches, and continued investment in technology and capacity expansion.

Improved operational efficiencies led the YoY profitability

The gross margin for the quarter stood at 34.5%, decreased by 46bps YoY (-61bps QoQ) due to higher raw material costs. For Q3FY25, the company's EBITDA stood at INR 4,570 Mn (+20.4% YoY/-5.3% QoQ). EBITDA margin increased by 15bps YoY (-44bps QoQ) to 10.9%. The YoY growth was driven by higher revenue, improved operational efficiencies, and cost optimization initiatives. PAT for the quarter increased by 20.2% YoY (-5.1% QoQ) to INR 2,326 Mn, showing robust revenue and operating performance.

Uno Minda strengthens EV focus with expansion, innovation, and strategic partnerships

Uno Minda reported strong Q3FY25 performance, driven by a 45% YoY rise in EV revenue to INR 2,380 Mn and double-digit growth across switching, lighting, and casting segments. Backed by a robust INR 27,900 Mn capex for FY25E, the company is expanding capacity in alloy wheels, lighting, and EVs. New plants at Kharkhoda and Supa are expected by FY26E. Revenue from controllers and ADAS stood at INR 3,590 Mn. Despite CV and export headwinds, strategic tie-ups, tech-led product diversification, and PLI-led policy tailwinds support a strong long-term growth outlook.

We expect Revenue/EBITDA/Adj. PAT to grow by 20.8%/ 23.4%/ 27.7% CAGR over FY24-27E. We apply a P/E multiple of 39.0x on FY27E EPS of INR 31.0, resulting in a target price of INR 1,208/share. This implies a left-over upside of 35.7% from the CMP. We have a 'BUY' rating on Uno Minda Ltd. since 7th Feb 2025.

Key Financials

Particulars (INR Mn)	FY24	FY25E	FY26E	FY27E
Revenue	1,40,309	1,67,407	1,98,991	2,47,437
EBITDA	15,853	19,134	23,591	29,774
PAT	8,803	10,099	13,102	17,787
EPS	15.4	17.6	22.9	31.0
EBITDA Margin	11.3%	11.4%	11.9%	12.0%
NPM	6.1%	6.0%	6.6%	7.2%


Source: DevenChoksey Research

Shareholding Pattern (%)

Particulars	Dec-24	Sep-24	Jun-24
Promoters	68.8	68.8	68.8
FIIIs	9.9	9.7	8.7
DIIIs	15.5	15.3	16.4
Others	5.9	6.3	6.2
Total	100	100	100

Source: BSE

Share price performance



Source: BSE

Past Performance Summary: For Investment Period Achieved*

Companies	Potential Upside Expected (%)	Return on Highest Price (%)
Investpro February 2024		
Ashok Leyland	24.2%	45.5%
Credit Access Grameen	21.2%	2.7%
HCL Tech	8.1%	4.5%
HDFC AMC	9.9%	17.9%
SBI Life Insurance	15.5%	21.3%
Sun Pharma	8.8%	16.7%
Investpro May 2024		
ACC Cement Ltd.	15.5%	12.3%
Axis Bank Ltd.	17.8%	17.3%
Gujarat Fluorochemicals	8.5%	36.1%
Laurus Labs Ltd.	12.5%	15.9%
Lupin Ltd.	7.4%	39.7%
Maruti Suzuki Ltd	19.9%	9.5%
Invest Pro August 2024		
Ashok Leyland Ltd.	15.6%	8.5%
Bajaj Finserv Ltd.	23.4%	29.4%
Happiest Minds Ltd.	15.1%	7.5%
Nestle India Ltd.	8.4%	10.6%
Pitti Engineering Ltd.	20.5%	32.1%
Poonawalla Fincorp Ltd.	31.5%	19.5%

Companies	Potential Upside Expected (%)	Return on Highest Price (%)
Investpro March 2024		
Cipla Ltd.	8.2%	14.2%
Fineotex Chemical Ltd.	40.6%	4.5%
Pitti Engineering Ltd.	28.7%	81.5%
Supriya Lifescience Ltd.	8.7%	56.1%
Tata Consumer Products Ltd.	12.5%	4.3%
Tata Motors Ltd	7.4%	19.5%
Investpro June 2024		
Aurobindo Pharma Ltd.	8.2%	33.0%
Bajaj Auto Ltd.	11.0%	38.1%
Glenmark Pharmaceuticals Ltd.	25.0%	63.1%
HDFC Bank Ltd.	15.6%	23.9%
State Bank of India Ltd.	25.8%	16.9%
Varun Beverages Ltd.	22.6%	20.9%
Invest Pro September 2024		
Archean Chemical Industries Ltd	30.8%	4.5%
Axis Bank Ltd.	12.8%	7.5%
Cholamandalam Investment & Finance Company Ltd.	7.0%	10.0%
Maruti Suzuki India Ltd.	14.1%	9.2%
PI Industries Ltd.	14.2%	5.8%
UltraTech Cement Ltd	6.2%	6.0%

Companies	Potential Upside Expected (%)	Return on Highest Price (%)
Investpro April 2024		
Granules	7.6%	62.5%
ICICI Bank	15.6%	25.9%
IndusInd Bank Ltd.	25.1%	1.1%
Minda Corporation Ltd	17.9%	58.1%
Uno Minda Ltd.	12.3%	81.3%
Zydus Lifesciences Ltd	11.5%	33.3%
Investpro July 2024		
Bajaj Finance Ltd.	12.6%	10.1%
Balaji Amines Ltd.	9.8%	5.9%
DCX Systems Ltd.	16.9%	1.4%
SBI Life Insurance Company Ltd	13.1%	28.3%
Shree Cement Ltd.	11.7%	4.3%
Tata Consultancy Service Ltd	4.3%	14.0%
Invest Pro October 2024		
ACC Cement Ltd.	16.3%	1.3%
Glenmark Pharmaceuticals Ltd.	13.1%	9.3%
Godrej Consumer Ltd	10.6%	1.2%
Rossari Biotech Ltd	13.9%	0.9%
State Bank of India Ltd.	28.2%	11.1%
Tata Motors	18.6%	2.3%

Notes: 1. *Investment Period for stock picks is 6 months from the date of the recommendations provided; and Return calculated on 6 months highest price.

2. Green depicts Outperformance, Yellow depicts Achieved(range -3% till potential upside), White depicts Partially Achieved & Red depicts Not achieved.

Performance Summary: For Investment Period Open*

Companies	Potential Upside Expected (%)	Return on Highest Price (%)
Invest Pro November 2024		
Cyient DLM Ltd	33.0%	17.4%
HDFC Asset Management Company Ltd.	25.8%	7.4%
ICICI Bank Ltd	17.5%	7.5%
Laxmi Organic Industries Ltd.	10.4%	5.1%
Lupin Ltd	11.7%	9.8%
Varun Beverages Ltd	24.2%	11.7%
Companies	Potential Upside Expected (%)	Return on Highest Price (%)
Invest Pro Febuary 2025		
Adani Wilmar Ltd	9.2%	1.1%
Cipla Ltd.	10.3%	5.9%
HDFC Life Insurance Company Ltd	31.0%	11.5%
Kotak Mahindra Bank Ltd	12.1%	14.1%
Laurus Labs Ltd	12.3%	5.6%
UltraTech Cement Ltd	10.6%	2.1%

Companies	Potential Upside Expected (%)	Return on Highest Price (%)
Invest Pro December 2024		
Gujarat Fluorochemicals Ltd.	12.2%	20.2%
Minda Corp Ltd.	9.9%	29.5%
Sun Pharma Ltd.	8.7%	8.4%
Tata Consumer Ltd.	18.7%	30.3%
Uno Minda Ltd	20.5%	22.6%
UPL Ltd.	6.5%	8.0%
Companies	Potential Upside Expected (%)	Return on Highest Price (%)
Invest Pro March 2025		
Divis Laboratories Ltd	16.2%	7.3%
HDFC AMC Ltd.	37.2%	12.8%
Shree Cement Ltd	10.6%	12.8%
Tech Mahindra Ltd	20.6%	4.4%
Varun Beverages Ltd	43.8%	22.2%
Zydus Lifesciences Ltd	38.0%	9.0%

Companies	Potential Upside Expected (%)	Return on Highest Price (%)
Invest Pro January 2025		
Archean Chemical	33.0%	0.9%
Aurobindo Pharma Ltd.	17.9%	1.2%
Bajaj Finance Ltd.	9.2%	25.3%
Cholamandalam Invt & Fin Co. Ltd.	20.4%	24.2%
Maruti Suzuki Ltd	13.2%	13.4%
Pitti Eng. Ltd	14.7%	3.5%

Notes: 1. *Investment Period for stock picks is 6 months from the date of the recommendations provided; and Return calculated on 6 months highest price.
2. Green depicts Outperformance, Yellow depicts Achieved(range -3% till potential upside), White depicts Partially Achieved & Red depicts Not achieved.

ANALYST CERTIFICATION:

We, **Karan Kamdar** (CA), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & Conditions and other disclosures:

DRChoksey FinServ Private Limited (hereinafter referred to as DCFPL) is a registered member of SEBI as a Research Entity vide Registration No. INH000011246 under SEBI (Research Analyst) Regulations, 2014, Portfolio Managers Entity vide Registration No. INP000007906 under SEBI (PORTFOLIO MANAGERS) Regulations, 2020 & Investment Adviser Entity vide Registration No. INA000017903 under SEBI (INVESTMENT ADVISERS) REGULATIONS, 2013.

The information and opinions in this report have been prepared by DCFPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of DCFPL. While we would endeavor to update the information herein on a reasonable basis, DCFPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent DCFPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or DCFPL policies, in circumstances where DCFPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. DCFPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. DCFPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

We submit that no material disciplinary action has been taken on DCFPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

DCFPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, We, **Karan Kamdar** Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

DCFPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company

DCFPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. DCFPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither DCFPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

It is confirmed that **Karan Kamdar**, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

DCFPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company.

The securities quoted are for illustration only and are not recommendatory.

DCFPL (Research Entity) and its research analysts uses Artificial Intelligence tools.

DCFPL and or its Research analysts shall be solely responsible for the security, confidentiality and integrity of the client data, use of any other information or data for research services, research services based on output of Artificial Intelligence tools and compliance with any law for the time being in force.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DCFPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Investment in securities are subject to market risks, read all the documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Please send your feedback to research.retail@devenchoksey.com

DRChoksey FinServ Private Limited

CIN Number -U67100MH2020PTC352816

Registered Office and Corporate Office:

5th Floor Abhishek Building, Behind Monginis Cake Factory, Off New Link Road, Andheri West, Mumbai-400058